Home/ Stocks/ BCAB

BioAtla, Inc. Common Stock

BCAB XNAS

$4.84 +0.49 (+11.26%) ▲ 15-min delayed

Open

$4.36

High

$5.18

Low

$4.36

Volume

58.3K

Market Cap

$8.03M

About BioAtla, Inc. Common Stock

BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 41 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$2.00M	$-59,607,000	$-1.01
FY 2025	$2.00M	$-59,607,000	$-1.01
Q3 2025	$0	$-15,778,000	$-0.27
Q2 2025	$0	$-18,711,000	$-0.32

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 5, 2026

Calendar →

Related Market News

No specific coverage for BCAB yet. Check out our latest market news or earnings calendar.

Get BCAB Alerts

Stay ahead with breaking news, price alerts, and expert analysis on BioAtla, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.